CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2023		Dec. 31, 2022		Dec. 31, 2021
Operating Activities
Net income before allocation to noncontrolling interests		$ 2,340		$ 2,111		$ 2,034
Adjustments to reconcile net income before noncontrolling interests to net cash provided by/(used in) operating activities
Depreciation and amortization expense	[1],[2]	491		465		448
Share-based compensation expense		60		62		58
Asset write-offs and asset impairments		46		53		47
Net loss/(gain) on sales of assets		(118)		0		0
Provision for losses on inventory		115		76		46
Deferred taxes		(61)		(286)		(80)
Settlement of derivative contracts		0		114		0
Employee benefit plan contribution from Pfizer Inc.		0		3		3
Other non-cash adjustments		(8)		13		0
Other changes in assets and liabilities, net of acquisitions and divestitures:
Accounts receivable		(102)		(137)		(155)
Inventories		(361)		(486)		(366)
Other assets		(95)		35		(7)
Accounts payable		13		(29)		(17)
Other liabilities		67		(180)		227
Other tax accounts, net		(34)		98		(25)
Net cash provided by operating activities		2,353		1,912		2,213
Investing Activities
Capital expenditures		(732)		(586)		(477)
Acquisitions, net of cash acquired		(155)		(312)		(14)
Purchase of investments		(4)		(9)		(12)
Net proceeds from sale of assets		4		1		2
Proceeds from derivative instrument activity, net		12		23		44
Proceeds from sale of businesses, net of cash sold		96		0		0
Other investing activities		2		0		(1)
Net cash used in investing activities		(777)		(883)		(458)
Financing Activities
Increase/(decrease) in short-term borrowings, net		1		2		(4)
Principal payments on long-term debt		(1,350)		0		(600)
Proceeds from issuance of long-term debt—senior notes, net of discount		0		1,348		0
Payment of debt issuance costs		0		(10)		0
Payment of consideration related to previous acquisitions		(3)		(1)		(6)
Share-based compensation-related proceeds, net of taxes paid on withholding shares		27		(38)		(35)
Purchases of treasury stock		(1,092)		(1,594)		(743)
Cash dividends paid		(692)		(611)		(474)
Net cash used in financing activities		(3,109)		(904)		(1,862)
Effect of exchange-rate changes on cash and cash equivalents		(7)		(29)		(12)
Net (decrease)/increase in cash and cash equivalents		(1,540)		96		(119)
Cash and cash equivalents at beginning of period		2,041	[3]	3,581	[3]	3,485
Cash paid during the period for:
Income taxes		754		638		548
Interest, net of capitalized interest		295		242		253
Non-cash transactions:
Capital expenditures		2		3		6
Dividends payable		198		174		154
Excise tax accrued on net share repurchases, not paid		$ 10		$ 0		$ 0

[1] Certain production facilities are shared. Depreciation and amortization is allocated to the reportable operating segments based on estimates of where the benefits of the related assets are realized.

[2] Defined as income before provision for taxes on income.

[3] As of December 31, 2023 and 2022, includes $2 million and $4 million, respectively, of restricted cash.